Nexalin Secures Exclusive South America Deal, Targeting 300M Patients
Event summary
- Nexalin signs 10-year exclusive distribution deal with Inovanexa for Brazil and six other South American countries, covering 300M people.
- Initial 100-device commercialization program includes binding purchase order for 10 devices, with clinical pilot targeted within 90 days.
- Distributor to establish local manufacturing in Brazil at zero capital cost to Nexalin, with recurring royalty revenue on devices and disposables.
- Nexalin retains full IP ownership while earning fixed per-device compensation and royalties on locally manufactured products.
- Deal follows ANVISA approval and clinical trial reporting 77.8% anxiety response rate at University of São Paulo.
The big picture
This deal marks Nexalin's first major commercial partnership following years of regulatory and clinical groundwork in Brazil. The agreement provides a capital-light path to revenue while establishing a template for future international expansion. With mental health disorders affecting millions in the region, the partnership could position Nexalin Sync as a standard treatment option if clinical results translate to commercial success.
What we're watching
- Execution Risk
- Whether Inovanexa can meet performance requirements and scale manufacturing to support commercial objectives.
- Market Adoption
- The pace at which Nexalin Sync gains traction in public and private healthcare sectors across South America.
- Revenue Transition
- How quickly Nexalin can shift from R&D phase to consistent revenue generation through this and future distribution deals.